KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
USA - NASDAQ:KRYS - US5011471027 - Common Stock
204.1 USD
-0.64 (-0.31%)
KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. KRYS may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, KRYS could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
KRYS had positive earnings in the past year.
KRYS had a positive operating cash flow in the past year.
In multiple years KRYS reported negative net income over the last 5 years.
In the past 5 years KRYS reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 16.04%, KRYS belongs to the best of the industry, outperforming 95.87% of the companies in the same industry.
With an excellent Return On Equity value of 17.48%, KRYS belongs to the best of the industry, outperforming 95.31% of the companies in the same industry.
KRYS has a Return On Invested Capital of 12.28%. This is amongst the best in the industry. KRYS outperforms 94.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROIC | 12.28% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 53.30%, KRYS belongs to the top of the industry, outperforming 98.69% of the companies in the same industry.
KRYS has a better Operating Margin (42.40%) than 99.06% of its industry peers.
KRYS's Gross Margin of 94.26% is amongst the best of the industry. KRYS outperforms 93.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KRYS is creating some value.
KRYS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KRYS has more shares outstanding
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 36.17 indicates that KRYS is not in any danger for bankruptcy at the moment.
KRYS's Altman-Z score of 36.17 is amongst the best of the industry. KRYS outperforms 95.68% of its industry peers.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 36.17 |
ROIC/WACC1.4
WACC8.76%
2.3 Liquidity
A Current Ratio of 10.14 indicates that KRYS has no problem at all paying its short term obligations.
KRYS's Current ratio of 10.14 is amongst the best of the industry. KRYS outperforms 81.43% of its industry peers.
KRYS has a Quick Ratio of 9.73. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.73, KRYS belongs to the top of the industry, outperforming 80.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 276.84% over the past year.
The Revenue has grown by 54.51% in the past year. This is a very strong growth!
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
3.2 Future
Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 60.32% on average per year.
Based on estimates for the next years, KRYS will show a very strong growth in Revenue. The Revenue will grow by 32.30% on average per year.
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y60.32%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y32.3%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 30.60, KRYS can be considered very expensive at the moment.
91.93% of the companies in the same industry are more expensive than KRYS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of KRYS to the average of the S&P500 Index (25.47), we can say KRYS is valued slightly more expensively.
With a Price/Forward Earnings ratio of 25.96, KRYS can be considered very expensive at the moment.
KRYS's Price/Forward Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.56% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.42. KRYS is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.6 | ||
| Fwd PE | 25.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaply inside the industry as 92.50% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.67 | ||
| EV/EBITDA | 29.64 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KRYS has a very decent profitability rating, which may justify a higher PE ratio.
KRYS's earnings are expected to grow with 55.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y62.16%
EPS Next 3Y55.07%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KRYS (11/19/2025, 2:58:08 PM)
204.1
-0.64 (-0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.05%
Inst Owner Change2.75%
Ins Owners11.86%
Ins Owner Change-1.53%
Market Cap5.91B
Revenue(TTM)373.16M
Net Income(TTM)198.91M
Analysts84.44
Price Target219.95 (7.77%)
Short Float %11.62%
Short Ratio8.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.19%
Min EPS beat(2)12.14%
Max EPS beat(2)140.23%
EPS beat(4)3
Avg EPS beat(4)41.54%
Min EPS beat(4)-13.89%
Max EPS beat(4)140.23%
EPS beat(8)4
Avg EPS beat(8)30.53%
EPS beat(12)5
Avg EPS beat(12)2.39%
EPS beat(16)7
Avg EPS beat(16)0.53%
Revenue beat(2)2
Avg Revenue beat(2)2.66%
Min Revenue beat(2)2.42%
Max Revenue beat(2)2.89%
Revenue beat(4)2
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.89%
Revenue beat(8)4
Avg Revenue beat(8)4.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.77%
PT rev (3m)4.63%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-4.58%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-11.47%
Revenue NQ rev (1m)0.92%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.6 | ||
| Fwd PE | 25.96 | ||
| P/S | 15.83 | ||
| P/FCF | 35.67 | ||
| P/OCF | 33.52 | ||
| P/B | 5.19 | ||
| P/tB | 5.19 | ||
| EV/EBITDA | 29.64 |
EPS(TTM)6.67
EY3.27%
EPS(NY)7.86
Fwd EY3.85%
FCF(TTM)5.72
FCFY2.8%
OCF(TTM)6.09
OCFY2.98%
SpS12.89
BVpS39.32
TBVpS39.32
PEG (NY)0.43
PEG (5Y)N/A
Graham Number76.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| ROCE | 13.77% | ||
| ROIC | 12.28% | ||
| ROICexc | 33.76% | ||
| ROICexgc | 33.76% | ||
| OM | 42.4% | ||
| PM (TTM) | 53.3% | ||
| GM | 94.26% | ||
| FCFM | 44.37% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 213.54% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.96% | ||
| Profit Quality | 83.25% | ||
| Current Ratio | 10.14 | ||
| Quick Ratio | 9.73 | ||
| Altman-Z | 36.17 |
F-Score7
WACC8.76%
ROIC/WACC1.4
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)276.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%192.31%
EPS Next Y70.36%
EPS Next 2Y62.16%
EPS Next 3Y55.07%
EPS Next 5Y60.32%
Revenue 1Y (TTM)54.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.65%
Revenue Next Year32.01%
Revenue Next 2Y39.8%
Revenue Next 3Y41.2%
Revenue Next 5Y32.3%
EBIT growth 1Y143.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y239.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.59%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status of KRYSTAL BIOTECH INC (KRYS) stock?
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 9 / 10.